Protocol Ledger

NCT05430854 · Phase II · TERMINATED

Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study

Interventional Phase II clinical trial protocol NCT05430854 sponsored by Amgen in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-06-01 Enrollment: 155 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05430854
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)155 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05430854
Protocol FieldVerified Registry Value
NCT IdentifierNCT05430854
Consolidated Lead SponsorAmgen
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment155 participants (ACTUAL)
Registered Start Date2022-06-01
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05430854
Hospital Research SiteLocationSite Profile
Emory Winship Cancer InstituteAtlanta, GAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI